Silq Technologies Corp. and NuSil Technology LLC Announce Collaboration Agreement to Drive Broad-based Adoption of Silq’s Novel Surface Treatment Technology
Silq Technologies and NuSil Technology , an Avantor (NYSE: AVTR) subsidiary, have formed a collaboration agreement to implement Silq's zwitterionic surface treatment technology on medical devices made with NuSil silicone products. The technology has shown potential to reduce medical implant-associated infections and complications without antibiotics, while also mitigating fibrosis, thrombosis, and enhancing surface lubricity.
Silq, a UCLA spin-off company, has developed a scalable method for applying permanent zwitterion surface treatment to implantable devices. Their ClearTract® Foley catheter, already FDA-cleared and being commercialized in the US, has shown promising results in preliminary clinical trials, with final results pending publication.
The partnership aims to expand the technology's application to various implantable medical devices that currently face complications leading to infections and premature device failure.
Silq Technologies e NuSil Technology, una sussidiaria di Avantor (NYSE: AVTR), hanno stipulato un accordo di collaborazione per implementare la tecnologia di trattamento superficiale zwitterionico di Silq su dispositivi medici realizzati con prodotti in silicone NuSil. Questa tecnologia ha dimostrato il potenziale di ridurre le infezioni e le complicazioni associate agli impianti medici senza l'uso di antibiotici, oltre a mitigare la fibrosi, la trombosi e migliorare la lubrificazione della superficie.
Silq, una spin-off dell'UCLA, ha sviluppato un metodo scalabile per applicare un trattamento superficiale zwitterionico permanente ai dispositivi impiantabili. Il loro catetere Foley ClearTract®, già approvato dalla FDA e in fase di commercializzazione negli Stati Uniti, ha mostrato risultati promettenti in prove cliniche preliminari, con i risultati finali in attesa di pubblicazione.
La partnership mira ad ampliare l'applicazione della tecnologia a vari dispositivi medici impiantabili che attualmente affrontano complicazioni che portano a infezioni e fallimenti prematuri dei dispositivi.
Silq Technologies y NuSil Technology, una subsidiaria de Avantor (NYSE: AVTR), han formado un acuerdo de colaboración para implementar la tecnología de tratamiento superficial zwitteriónico de Silq en dispositivos médicos fabricados con productos de silicona NuSil. La tecnología ha mostrado potencial para reducir infecciones y complicaciones asociadas a implantes médicos sin antibióticos, además de mitigar la fibrosis, la trombosis y mejorar la lubricidad de la superficie.
Silq, una empresa derivada de UCLA, ha desarrollado un método escalable para aplicar un tratamiento superficial zwitteriónico permanente a dispositivos implantables. Su catéter Foley ClearTract®, ya aprobado por la FDA y en proceso de comercialización en EE. UU., ha mostrado resultados prometedores en ensayos clínicos preliminares, con resultados finales pendientes de publicación.
La asociación tiene como objetivo ampliar la aplicación de la tecnología a varios dispositivos médicos implantables que actualmente enfrentan complicaciones que conducen a infecciones y fallos prematuros del dispositivo.
실크 테크놀로지와 누실 테크놀로지는 아반토르(NYSE: AVTR)의 자회사로서, 실크의 zwitterionic 표면 처리 기술을 누실 실리콘 제품으로 제작된 의료 기기에 적용하기 위한 협력 계약을 체결했습니다. 이 기술은 항생제를 사용하지 않고도 의료 임플란트와 관련된 감염 및 합병증을 줄일 수 있는 잠재력을 보여주며, 섬유증 및 혈전증을 완화하고 표면의 윤활성을 향상시킵니다.
실크는 UCLA의 스핀오프 기업으로, 이식 가능한 장치에 영구적인 zwitterion 표면 처리를 적용하기 위한 확장 가능한 방법을 개발했습니다. 그들의 클리어트랙® 폴리 카테터는 이미 FDA 승인을 받았고 미국에서 상용화되고 있으며, 초기 임상 시험에서 유망한 결과를 보여주었으며, 최종 결과는 출판을 기다리고 있습니다.
이 파트너십은 현재 감염 및 조기 장치 실패로 이어지는 합병증에 직면해 있는 다양한 이식 가능한 의료 기기에 기술의 적용을 확대하는 것을 목표로 하고 있습니다.
Silq Technologies et NuSil Technology, une filiale d'Avantor (NYSE: AVTR), ont conclu un accord de collaboration pour mettre en œuvre la technologie de traitement de surface zwitterionique de Silq sur des dispositifs médicaux fabriqués avec des produits en silicone NuSil. Cette technologie a montré un potentiel pour réduire les infections et les complications associées aux implants médicaux sans antibiotiques, tout en atténuant la fibrose, la thrombose et en améliorant la lubrification de la surface.
Silq, une spin-off de l'UCLA, a développé une méthode évolutive pour appliquer un traitement de surface zwitterionique permanent aux dispositifs implantables. Leur cathéter Foley ClearTract®, déjà approuvé par la FDA et en cours de commercialisation aux États-Unis, a montré des résultats prometteurs lors d'essais cliniques préliminaires, les résultats finaux étant en attente de publication.
Le partenariat vise à étendre l'application de la technologie à divers dispositifs médicaux implantables qui font actuellement face à des complications entraînant des infections et des défaillances prématurées des dispositifs.
Silq Technologies und NuSil Technology, eine Tochtergesellschaft von Avantor (NYSE: AVTR), haben eine Kooperationsvereinbarung getroffen, um die zwitterionische Oberflächenbehandlungstechnologie von Silq auf medizinischen Geräten aus NuSil-Silikonprodukten anzuwenden. Die Technologie hat das Potenzial gezeigt, medizinische Implantat-assoziierte Infektionen und Komplikationen ohne Antibiotika zu reduzieren, während sie auch Fibrose, Thrombose mildert und die Oberflächenbeschichtung verbessert.
Silq, ein Spin-off der UCLA, hat eine skalierbare Methode zur Anwendung einer permanenten zwitterionischen Oberflächenbehandlung auf implantierbaren Geräten entwickelt. Ihr ClearTract® Foley-Katheter, der bereits von der FDA genehmigt ist und in den USA kommerzialisiert wird, hat in vorläufigen klinischen Studien vielversprechende Ergebnisse gezeigt, während die endgültigen Ergebnisse noch veröffentlicht werden müssen.
Die Partnerschaft zielt darauf ab, die Anwendung der Technologie auf verschiedene implantierbare medizinische Geräte auszudehnen, die derzeit Komplikationen gegenüberstehen, die zu Infektionen und vorzeitigem Versagen der Geräte führen.
- FDA clearance and ongoing commercialization of ClearTract® Foley catheter
- Preliminary clinical trials showing favorable outcomes and economic benefits
- Partnership with major silicone supplier NuSil/Avantor expands market reach
- Scalable manufacturing solution for previously challenging zwitterion technology
- None.
Insights
This strategic collaboration represents a significant advancement in medical device technology, with substantial implications for Avantor's market position in the $180 billion global medical device market. The partnership leverages NuSil's established presence in medical-grade silicones with Silq's breakthrough zwitterionic surface treatment technology, which addresses a critical unmet need in implantable medical devices.
The technology's FDA clearance for Foley catheters serves as a important proof-of-concept, demonstrating both regulatory viability and clinical effectiveness. The ongoing clinical trials showing favorable outcomes significantly de-risk future applications across other medical devices. This creates a clear pathway for expanded regulatory approvals, potentially accelerating time-to-market for new products.
From a revenue perspective, this collaboration positions Avantor to capture high-margin opportunities in the medical implant space. The technology's ability to reduce complications and improve patient outcomes could lead to premium pricing power and broader adoption across healthcare systems. The recurring nature of medical device sales, combined with the potential for reduced warranty claims and liability costs, suggests a positive impact on long-term profitability.
The competitive moat is particularly noteworthy. While zwitterionic surface technology has been studied for decades, Silq's scalable manufacturing solution addresses previous commercial limitations. This first-mover advantage in commercialization, combined with NuSil's established distribution channels and customer relationships, creates significant barriers to entry for competitors.
For Avantor, this represents a strategic expansion of their high-value solutions portfolio, potentially driving both top-line growth through new applications and bottom-line improvements through enhanced margins. The collaboration also aligns with healthcare's shift toward prevention and reduced complications, positioning the company favorably amid increasing focus on healthcare economics and patient outcomes.
Zwitterion surface technology has been a major subject of research in academia for several decades because of its potential to reduce medical implant-associated infections and complications without the use of antibiotics. Zwitterion functionalized surfaces have also been shown to mitigate fibrosis and thrombosis, reduce encrustation and enhance surface lubricity. However, manufacturing and economic challenges have largely prevented their commercial applicability.
Silq Technologies, a company spun out of the University of
Silq and NuSil’s collaboration will explore opportunities to apply Silq’s technology on a wide range of implantable medical devices that are currently prone to complications resulting in infections, premature device failure, and surgical removal and replacement.
“We are extremely excited by the potential our collaboration with NuSil offers,” said D. Verne Sharma, CEO of Silq. “This partnership aims to address challenges currently faced by device manufacturers and we believe it will expedite our mission of utilizing zwitterion technology across a diverse array of implantable applications.”
“NuSil is excited to collaborate with Silq, a leader in applying permanent zwitterion surface treatments to implantable medical devices,” said Rich Best, General Manager of NuSil. “The potential synergies between these surface coatings and our customized silicone solutions could drive new innovations in emerging therapies and medical devices and bring significant benefit to patients. This collaboration aligns with our mission to set science in motion to create a better world.”
About Silq Technologies Corporation
Silq Technologies is a leader in advanced biomaterials. The company’s patented zwitterion-based technology and scalable manufacturing platform deliver a unique surface treatment that is designed to resist the adhesion of organic material, thereby improving the effectiveness, efficiency, and safety of a broad range of commercial products. The technology can be used in medical devices, medical implants, microfluidics, biopharma applications, water treatment facilities, and much more. The company’s first product, a surface treated silicone Foley catheter, has been cleared for sale by the FDA and is in early stages of commercialization. Silq is working with several medical device manufacturers to evaluate the clinical benefits of Silq’s zwitterion coating on their implantable products. For additional information, visit https://www.silq.tech/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219365843/en/
Media Contact:
STAKE Investor Relations
hello@stakeir.com
Source: Silq Technologies Corporation
FAQ
What is the purpose of Silq Technologies and Avantor (AVTR) collaboration agreement?
What are the key benefits of Silq's zwitterionic surface treatment technology?
Has Silq's ClearTract® Foley catheter received FDA approval?
How will the AVTR partnership impact Silq's market reach?
What clinical evidence supports Silq's technology effectiveness?
